Long prodromal symptoms of neuroleptic malignant syndrome in patient with intellectual developmental disorder-A case report.

Autor: Sadati S; Psychiatry and Behavioral Sciences Research Center, Addiction Institute, Mazandaran University of Medical Sciences, Sari, Iran.; Department of Psychiatry, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran., Elyasi F; Faculty of Medicine, Sexual and Reproductive Health Research Center, Psychiatry and Behavioral Sciences Research Center, Addiction Institute, Mazandaran University of Medical Sciences, Sari, Iran., Shyasi Z; Department of Psychiatry, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran., Rouhanizadeh B; Health Analytics Department, Carilion Clinic, Roanoke, Virginia, USA.
Jazyk: angličtina
Zdroj: Neuropsychopharmacology reports [Neuropsychopharmacol Rep] 2024 Sep; Vol. 44 (3), pp. 521-525. Date of Electronic Publication: 2024 Jun 04.
DOI: 10.1002/npr2.12454
Abstrakt: Background: Neuroleptic malignant syndrome (NMS) is a rare and potentially life-threatening condition that may arise at any point during treatment and is often associated with adverse reactions to dopamine-blocking agents. This syndrome is normally characterized by features such as muscle rigidity, alteration in consciousness, autonomic instability, and leukocytosis.
Aim: The aim of this study is to investigate a borderline intellectual functioning (BIF) case in which NMS with insidious disease progression and long prodromal symptoms was developed.
Case Presentation: The investigated patient was a 38-year-old female diagnosed with bipolar disorder and a variety of corresponding disorders. The patient exhibited gastrointestinal symptoms and restlessness in the weeks leading up to the study, subsequent to the administration of elevated doses of haloperidol, risperidone, and lithium. In addition, she was hospitalized for restlessness and aggressiveness in the summer of 2023. Furthermore, due to her chief complaint, she received parenteral haloperidol twice in the emergency room, subsequently experiencing fever, altered consciousness, generalized rigidity, and dysphagia. Moreover, the patient's initial creatine phosphokinase (CPK) level was 2550 IU/L, and she was hospitalized in an intensive care unit with the diagnosis of NMS for 8 days.
Conclusions: This case study highlights the necessity of being attentive about prodromal symptoms of NMS and emergent interventions.
(© 2024 The Author(s). Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology.)
Databáze: MEDLINE
Externí odkaz: